ANI PHARMACEUTICALS, INC Share-based Payment Arrangement, Expense, Tax Benefit
ANI PHARMACEUTICALS, INC (ANIP) reported Share-based Payment Arrangement, Expense, Tax Benefit of $1.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-02-27
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense, tax benefit for fiscal 2025 was $1.40M, a 50.00% decline from fiscal 2024.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense, tax benefit for fiscal 2024 was $2.80M, a 15.15% decline from fiscal 2023.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense, tax benefit for fiscal 2023 was $3.30M, a 94.12% increase from fiscal 2022.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense, tax benefit for fiscal 2022 was $1.70M, a 70.00% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 12 month | Share-based Payment Arrangement, Expense, Tax Benefit 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.40M 10-K · filed 2026-02-27 | |
| 2024-12-31 | $2.80M 10-K · filed 2026-02-27 | |
| 2023-12-31 | $3.30M 10-K · filed 2026-02-27 | |
| 2022-12-31 | $1.70M 10-K · filed 2025-02-28 | |
| 2021-12-31 | $1.00M 10-K · filed 2024-02-29 | |
| 2020-12-31 | $1.60M 10-K · filed 2023-03-09 | |
| 2019-12-31 | $1.40M 10-K · filed 2022-03-15 | |
| 2018-12-31 | $1.20M 10-K · filed 2021-03-11 | |
| 2017-12-31 | $600.00K 10-K · filed 2020-02-27 | |
| 2016-12-31 | $1.00M 10-K · filed 2019-02-27 | |
| 2015-12-31 | $400.00K 10-K · filed 2018-02-27 | $2.00M 10-K · filed 2016-02-23 |
| 2014-12-31 | $600.00K 10-K · filed 2017-03-02 | $4.40M 10-K · filed 2015-02-23 |
| 2013-12-31 | $0.00 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |